Yoko Mullen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoko Mullen has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Fouad Kandeel
From the *Southern California Islet Cell Resources Center, Department of Diabetes, Endocrinology and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA; †Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery Kobe University Graduate School of Medicine, Kobe, Japan; and ‡Department of Immunology, Beckman Research Institute of the City of Hope, Duarte, CA
6 shared publicationsIvan Todorov
From the *Southern California Islet Cell Resources Center, Department of Diabetes, Endocrinology and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA; †Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery Kobe University Graduate School of Medicine, Kobe, Japan; and ‡Department of Immunology, Beckman Research Institute of the City of Hope, Duarte, CA
5 shared publicationsJeffrey Rawson
Southern California Islet Cell Resources Center, Department of Diabetes, Endocrinology and Metabolism, Beckman Research Institute of the City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA
4 shared publicationsKeiko Omori
Division of Developmental and Translational Diabetes and Endocrinology Research, Department of Diabetes and Metabolic Researches, Beckman Research Institute of City of Hope, 1500 E. Duarte Rd., Duarte, CA 91010, USA
4 shared publications- Kevin Ferreri
Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute of City of Hope, Duarte, California, United States of America
4 shared publications Sadaki Asari
Southern California Islet Cell Resources Center, Department of Diabetes, Endocrinology and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA, USA
4 shared publications
Latest Publications
- 18 October 2019
- Published by Elsevier in Experimental Gerontology
- Vol. 128, 110739
Isolated pancreatic islet yield and quality is inversely related to organ donor age in rats
- 18 October 2019
- Published by Elsevier in Experimental Gerontology
- Vol. 128, 110739
Isolated pancreatic islet yield and quality is inversely related to organ donor age in rats
- 1 May 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 486 (3) , 817-823
Oxygenated thawing and rewarming alleviate rewarming injury of cryopreserved pancreatic islets
- 1 May 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 486 (3) , 817-823
Oxygenated thawing and rewarming alleviate rewarming injury of cryopreserved pancreatic islets
- Open Access
- 1 April 2017
- Published by Wolters Kluwer Health in Pancreas
- Vol. 46 (4) , 455-466
Development of the Nonobese Diabetic Mouse and Contribution of Animal Models for Understanding Type 1 Diabetes
In 1974, the discovery of a mouse and a rat that spontaneously developed hyperglycemia led to the development of 2 autoimmune diabetes models: nonobese diabetic (NOD) mouse and Bio-Breeding rat. These models have contributed to our understanding of autoimmune diabetes, provided tools to dissect autoimmune islet damage, and facilitated development of early detection, prevention, and treatment of type 1 diabetes. The genetic characterization, monoclonal antibodies, and congenic strains have made NOD mice especially useful. Although the establishment of the inbred NOD mouse strain was documented by Makino et al (Jikken Dobutsu. 1980;29:1–13), this review will focus on the not-as-well-known history leading to the discovery of a glycosuric female mouse by Yoshihiro Tochino. This discovery was spearheaded by years of effort by Japanese scientists from different disciplines and dedicated animal care personnel and by the support of the Shionogi Pharmaceutical Company, Osaka, Japan. The history is based on the early literature, mostly written in Japanese, and personal communications especially with Dr Tochino, who was involved in diabetes animal model development and who contributed to the release of NOD mice to the international scientific community. This article also reviews the scientific contributions made by the Bio-Breeding rat to autoimmune diabetes.
- 1 April 2017
- Published by Wolters Kluwer Health in Pancreas
- Vol. 46 (4) , 455-466
Open AccessDevelopment of the Nonobese Diabetic Mouse and Contribution of Animal Models for Understanding Type 1 Diabetes
In 1974, the discovery of a mouse and a rat that spontaneously developed hyperglycemia led to the development of 2 autoimmune diabetes models: nonobese diabetic (NOD) mouse and Bio-Breeding rat. These models have contributed to our understanding of autoimmune diabetes, provided tools to dissect autoimmune islet damage, and facilitated development of early detection, prevention, and treatment of type 1 diabetes. The genetic characterization, monoclonal antibodies, and congenic strains have made NOD mice especially useful. Although the establishment of the inbred NOD mouse strain was documented by Makino et al (Jikken Dobutsu. 1980;29:1–13), this review will focus on the not-as-well-known history leading to the discovery of a glycosuric female mouse by Yoshihiro Tochino. This discovery was spearheaded by years of effort by Japanese scientists from different disciplines and dedicated animal care personnel and by the support of the Shionogi Pharmaceutical Company, Osaka, Japan. The history is based on the early literature, mostly written in Japanese, and personal communications especially with Dr Tochino, who was involved in diabetes animal model development and who contributed to the release of NOD mice to the international scientific community. This article also reviews the scientific contributions made by the Bio-Breeding rat to autoimmune diabetes.
- 1 May 2013
- Published by Elsevier in Biomaterials
- Vol. 34 (16) , 3984-3991
Maintaining functional islets through encapsulation in an injectable saccharide–peptide hydrogel
- 1 May 2013
- Published by Elsevier in Biomaterials
- Vol. 34 (16) , 3984-3991
Maintaining functional islets through encapsulation in an injectable saccharide–peptide hydrogel
- 1 August 2011
- Published by Wolters Kluwer Health in Pancreas
- Vol. 40 (6) , 846-854
Mesenchymal Stem Cells Facilitate Mixed Hematopoietic Chimerism Induction and Prevent Onset of Diabetes in Nonobese Diabetic Mice
Objectives: Allogeneic mesenchymal stem cells (MSCs) and bone marrow cells (BMCs) were cotransplanted in nonobese diabetic mice after none myeloablative preconditioning and the development of chimerism, insulitis, diabetes, and graft-versus-host disease (GVHD) were monitored. Methods: Eight-week-old female nonobese diabetic mice were injected intravenously with 2 × 107 BMCs and 5 × 105 MSCs from C57BL/6 mice after treatment with 2 intraperitoneal injections of anti-CD3 antibody (days −7 and −4) and 3-Gy total body irradiation (day −1). Thereafter, blood glucose and chimerism were monitored on peripheral blood samples. Results: Stable mixed chimerism (3−>90% of donor phenotype) was induced in 63.2% of BMCs-MSCs recipients (n = 19) and 45.0% of BMCs-alone recipients (n = 20, P = 0.256). Insulitis was prevented, and euglycemia persisted for more than 18 weeks in 89.5% of BMCs-MSCs recipients including those with less than 3% chimerism and 55% of BM-alone recipients (P < 0.05). In controls, 9.1% of mice receiving preconditioning treatment alone (n = 11) and 16.7% of preconditioned mice receiving only MSCs (n = 12) were nondiabetic. Graft-versus-host disease was not detected in all mice. Conclusions: Coinjection of MSCs and BMCs increased the success rate in inducing chimerism and preventing insulitis and overt diabetes with no incidence of GVHD. Results also indicated that even microchimerism with less than 3% donor cells is sufficient for blocking autoimmunity. Abbreviations: Ab - antibody, BM - bone marrow, BMCs - bone marrow cells, FACS - fluorescence-activated cell sorting, GVHD - graft-versus-host disease, IL - interleukin, IV - intravenous(ly), L - ligand, mAb - monoclonal antibody, MLR - mixed lymphocyte reaction, MSCs - mesenchymal stem cells, NOD - nonobese diabetic, P - passage, PBLs - peripheral blood lymphocytes, PBS - phosphate-buffered saline, TBI - total body irradiation
- 1 August 2011
- Published by Wolters Kluwer Health in Pancreas
- Vol. 40 (6) , 846-854
Mesenchymal Stem Cells Facilitate Mixed Hematopoietic Chimerism Induction and Prevent Onset of Diabetes in Nonobese Diabetic Mice
Objectives: Allogeneic mesenchymal stem cells (MSCs) and bone marrow cells (BMCs) were cotransplanted in nonobese diabetic mice after none myeloablative preconditioning and the development of chimerism, insulitis, diabetes, and graft-versus-host disease (GVHD) were monitored. Methods: Eight-week-old female nonobese diabetic mice were injected intravenously with 2 × 107 BMCs and 5 × 105 MSCs from C57BL/6 mice after treatment with 2 intraperitoneal injections of anti-CD3 antibody (days −7 and −4) and 3-Gy total body irradiation (day −1). Thereafter, blood glucose and chimerism were monitored on peripheral blood samples. Results: Stable mixed chimerism (3−>90% of donor phenotype) was induced in 63.2% of BMCs-MSCs recipients (n = 19) and 45.0% of BMCs-alone recipients (n = 20, P = 0.256). Insulitis was prevented, and euglycemia persisted for more than 18 weeks in 89.5% of BMCs-MSCs recipients including those with less than 3% chimerism and 55% of BM-alone recipients (P < 0.05). In controls, 9.1% of mice receiving preconditioning treatment alone (n = 11) and 16.7% of preconditioned mice receiving only MSCs (n = 12) were nondiabetic. Graft-versus-host disease was not detected in all mice. Conclusions: Coinjection of MSCs and BMCs increased the success rate in inducing chimerism and preventing insulitis and overt diabetes with no incidence of GVHD. Results also indicated that even microchimerism with less than 3% donor cells is sufficient for blocking autoimmunity. Abbreviations: Ab - antibody, BM - bone marrow, BMCs - bone marrow cells, FACS - fluorescence-activated cell sorting, GVHD - graft-versus-host disease, IL - interleukin, IV - intravenous(ly), L - ligand, mAb - monoclonal antibody, MLR - mixed lymphocyte reaction, MSCs - mesenchymal stem cells, NOD - nonobese diabetic, P - passage, PBLs - peripheral blood lymphocytes, PBS - phosphate-buffered saline, TBI - total body irradiation
- 6 July 2011
- Published by Springer Nature in Diabetologia
- Vol. 54 (9) , 2474
Erratum to: mRNA of the pro-apoptotic gene BBC3 serves as a molecular marker for TNF-α-induced islet damage in humans
- 6 July 2011
- Published by Springer Nature in Diabetologia
- Vol. 54 (9) , 2474
Erratum to: mRNA of the pro-apoptotic gene BBC3 serves as a molecular marker for TNF-α-induced islet damage in humans
- 13 May 2011
- Published by Springer Nature in Diabetologia
- Vol. 54 (8) , 2056-2066
mRNA of the pro-apoptotic gene BBC3 serves as a molecular marker for TNF-α-induced islet damage in humans
Aims/hypothesis TNF-α plays important roles in the pathogenesis of type 1 and type 2 diabetes mellitus. In light of this, we examined the involvement of a pro-apoptotic gene, BBC3 (also known as PUMA), in TNF-α-mediated beta cell dysfunction and destruction in human islets. Methods Human islets were exposed in vitro to TNF-α alone or in combination with IFN-γ. Gene expression was assessed by RT-PCR using a set of single islets. Protein abundance and cellular localisation of BBC3 were assessed by immunoblot and immunohistochemistry. A marginal number of islets were transplanted into diabetic NODscid mice to correlate in vivo islet function with BBC3 expression. Results BBC3 and IL8 mRNA were upregulated in TNF-α-stimulated islets in a dose-dependent manner and enhanced through addition of IFN-γ, but not upregulated by IFN-γ alone. Immunohistochemistry revealed that TNF-α in combination with IFN-γ upregulated basal BBC3 abundance in the cytoplasm of beta cells along with the perinuclear clustering of mitochondria partially co-localised with BBC3. TNF-α alone did not induce beta cell death, but did abrogate preproinsulin precursor mRNA synthesis in response to high glucose stimulation, which was inversely associated with upregulation of BBC3 mRNA expression by TNF-α. Higher BBC3 mRNA expression in islets correlated with decreased graft function in vivo. Conclusions/interpretation These results suggest that BBC3 mRNA can serve as a molecular marker to detect early TNF-α-induced beta cell stress and may help identify islet-protective compounds for the treatment of diabetes.
- 13 May 2011
- Published by Springer Nature in Diabetologia
- Vol. 54 (8) , 2056-2066
mRNA of the pro-apoptotic gene BBC3 serves as a molecular marker for TNF-α-induced islet damage in humans
Aims/hypothesis TNF-α plays important roles in the pathogenesis of type 1 and type 2 diabetes mellitus. In light of this, we examined the involvement of a pro-apoptotic gene, BBC3 (also known as PUMA), in TNF-α-mediated beta cell dysfunction and destruction in human islets. Methods Human islets were exposed in vitro to TNF-α alone or in combination with IFN-γ. Gene expression was assessed by RT-PCR using a set of single islets. Protein abundance and cellular localisation of BBC3 were assessed by immunoblot and immunohistochemistry. A marginal number of islets were transplanted into diabetic NODscid mice to correlate in vivo islet function with BBC3 expression. Results BBC3 and IL8 mRNA were upregulated in TNF-α-stimulated islets in a dose-dependent manner and enhanced through addition of IFN-γ, but not upregulated by IFN-γ alone. Immunohistochemistry revealed that TNF-α in combination with IFN-γ upregulated basal BBC3 abundance in the cytoplasm of beta cells along with the perinuclear clustering of mitochondria partially co-localised with BBC3. TNF-α alone did not induce beta cell death, but did abrogate preproinsulin precursor mRNA synthesis in response to high glucose stimulation, which was inversely associated with upregulation of BBC3 mRNA expression by TNF-α. Higher BBC3 mRNA expression in islets correlated with decreased graft function in vivo. Conclusions/interpretation These results suggest that BBC3 mRNA can serve as a molecular marker to detect early TNF-α-induced beta cell stress and may help identify islet-protective compounds for the treatment of diabetes.
- 27 June 2010
- Published by Wolters Kluwer Health in Transplantation
- Vol. 89 (12) , 1438-1445
Mesenchymal Stem Cell and Islet Co-Transplantation Promotes Graft Revascularization and Function
Background. Bone marrow-derived mesenchymal stem cells (MSCs) are known to produce vascular endothelial growth factor. We hypothesize that co-transplantation of MSCs and islets promotes revascularization and improves islet graft function. Methods. Lewis rat islets were infused into the liver of streptozotocin-diabetic syngeneic recipients or transplanted under the renal capsule of nonobese diabetic severe combined immunodeficiency (NOD SCID) mice with MSCs isolated from Lewis bone marrow and expanded in culture. Results. Co-transplantation of 500 islets and 107 MSCs (islet-MSCs) reversed diabetes in all eight recipients, whereas islet-alone transplantation achieved euglycemia in 3 of 10 recipients. With 300 islets, five of nine islet-MSCs and 1 of 10 islets-alone recipients reversed diabetes. Results of intravenous glucose tolerance tests performed on day 56 were significantly better in islet-MSCs than islet-alone recipients. One week after transplantation, well-preserved islet structure and higher number of capillaries were found in the liver of islet-MSCs recipients, whereas islet-alone grafts were fragmented with very few capillaries. Islets showed a similar morphology when transplanted with MSCs in nonobese diabetic severe combined immunodeficiency mice with a significantly higher capillary per β-cell ratio than that in islet-alone grafts (0.135±0.046 vs. 0.052±0.028 capillary segments per β-cell, P<0.01). One week after transplantation, islets were surrounded by MSCs labeled with carboxyfluorescein succinimidyl ester or Qdot nanocrystals, and some labeled MSCs positively stained for vascular endothelial growth factor or von Willebrand factor. Conclusion. Our results demonstrate the improvement of islet graft morphology and function by co-transplantation with MSCs. This improvement is attributable, at least in part, to the promotion of graft revascularization mediated by MSCs.
- 27 June 2010
- Published by Wolters Kluwer Health in Transplantation
- Vol. 89 (12) , 1438-1445
Mesenchymal Stem Cell and Islet Co-Transplantation Promotes Graft Revascularization and Function
Background. Bone marrow-derived mesenchymal stem cells (MSCs) are known to produce vascular endothelial growth factor. We hypothesize that co-transplantation of MSCs and islets promotes revascularization and improves islet graft function. Methods. Lewis rat islets were infused into the liver of streptozotocin-diabetic syngeneic recipients or transplanted under the renal capsule of nonobese diabetic severe combined immunodeficiency (NOD SCID) mice with MSCs isolated from Lewis bone marrow and expanded in culture. Results. Co-transplantation of 500 islets and 107 MSCs (islet-MSCs) reversed diabetes in all eight recipients, whereas islet-alone transplantation achieved euglycemia in 3 of 10 recipients. With 300 islets, five of nine islet-MSCs and 1 of 10 islets-alone recipients reversed diabetes. Results of intravenous glucose tolerance tests performed on day 56 were significantly better in islet-MSCs than islet-alone recipients. One week after transplantation, well-preserved islet structure and higher number of capillaries were found in the liver of islet-MSCs recipients, whereas islet-alone grafts were fragmented with very few capillaries. Islets showed a similar morphology when transplanted with MSCs in nonobese diabetic severe combined immunodeficiency mice with a significantly higher capillary per β-cell ratio than that in islet-alone grafts (0.135±0.046 vs. 0.052±0.028 capillary segments per β-cell, P<0.01). One week after transplantation, islets were surrounded by MSCs labeled with carboxyfluorescein succinimidyl ester or Qdot nanocrystals, and some labeled MSCs positively stained for vascular endothelial growth factor or von Willebrand factor. Conclusion. Our results demonstrate the improvement of islet graft morphology and function by co-transplantation with MSCs. This improvement is attributable, at least in part, to the promotion of graft revascularization mediated by MSCs.
- 27 January 2010
- Published by Wolters Kluwer Health in Transplantation
- Vol. 89 (2) , 146-154
Microassay for Glucose-Induced Preproinsulin mRNA Expression to Assess Islet Functional Potency for Islet Transplantation
Background. The capacity for insulin synthesis in islets is important for islet transplantation to succeed. We developed a microassay that evaluates the potency of human islets by measuring changes in glucose-induced human insulin gene (INS) expression using a single islet in octuplicate samples. Methods. Poly (A)+ messenger RNA (mRNA) was purified from a set of single handpicked human islets. Glucose-induced mature (postspliced) and premature (prespliced) insulin mRNA were quantified by reverse-transcriptase polymerase chain reaction using several insulin mRNA primers designed at different locations including, intron, exon, and an exon-intron junction. Results. The synthesis of premature INS mRNA was significantly increased in islets exposed to high glucose for 16 vs. 4 hr (PINS mRNA showed no difference. Glucose-induced premature INS mRNA synthesis was attenuated in heat-damaged islets. Stimulation index (SI) calculated by normalizing premature by mature INS mRNA (SI_INS mRNA) positively correlated with SI of insulin release (SI_16h insulin) from the same set of islets during 16-hr incubation in high or low glucose media, and SI of glucose-mediated insulin release obtained from the same islet lot in a perifusion system (n=12). Furthermore, linear multiple regression analysis using SI_INS mRNA and SI_16h insulin predicted islet transplantation outcome in nonobese diabetic (NOD) scid mice (n=8). Conclusion. The measurement of glucose-induced premature INS mRNA normalized by mature INS mRNA can be used to assess the functional quality of human islets and may predict islet function after transplantation in type 1 diabetic patients.
- 27 January 2010
- Published by Wolters Kluwer Health in Transplantation
- Vol. 89 (2) , 146-154
Microassay for Glucose-Induced Preproinsulin mRNA Expression to Assess Islet Functional Potency for Islet Transplantation
Background. The capacity for insulin synthesis in islets is important for islet transplantation to succeed. We developed a microassay that evaluates the potency of human islets by measuring changes in glucose-induced human insulin gene (INS) expression using a single islet in octuplicate samples. Methods. Poly (A)+ messenger RNA (mRNA) was purified from a set of single handpicked human islets. Glucose-induced mature (postspliced) and premature (prespliced) insulin mRNA were quantified by reverse-transcriptase polymerase chain reaction using several insulin mRNA primers designed at different locations including, intron, exon, and an exon-intron junction. Results. The synthesis of premature INS mRNA was significantly increased in islets exposed to high glucose for 16 vs. 4 hr (PINS mRNA showed no difference. Glucose-induced premature INS mRNA synthesis was attenuated in heat-damaged islets. Stimulation index (SI) calculated by normalizing premature by mature INS mRNA (SI_INS mRNA) positively correlated with SI of insulin release (SI_16h insulin) from the same set of islets during 16-hr incubation in high or low glucose media, and SI of glucose-mediated insulin release obtained from the same islet lot in a perifusion system (n=12). Furthermore, linear multiple regression analysis using SI_INS mRNA and SI_16h insulin predicted islet transplantation outcome in nonobese diabetic (NOD) scid mice (n=8). Conclusion. The measurement of glucose-induced premature INS mRNA normalized by mature INS mRNA can be used to assess the functional quality of human islets and may predict islet function after transplantation in type 1 diabetic patients.
- 1 May 2009
- Published by Elsevier in Experimental Hematology
- Vol. 37 (5) , 604-615
Mesenchymal stem cells suppress B-cell terminal differentiation
- 1 May 2009
- Published by Elsevier in Experimental Hematology
- Vol. 37 (5) , 604-615
Mesenchymal stem cells suppress B-cell terminal differentiation